Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Establishing On-Site Reference Values for 123I-FP-CIT SPECT (DaTSCAN®) Using a Cohort of Individuals with Non-Degenerative Conditions

  • 380 Accesses

  • 19 Citations

Abstract

Purpose

To overcome the issue of reference values for DaTSCAN® requiring healthy controls, we propose an original approach using scans from individuals with non-degenerative conditions performed at one single center following the same acquisition protocol.

Procedures

From a cohort of 970 consecutive patients, we identified 182 patients with a clinical diagnosis of non-degenerative parkinsonism or tremor and a visually normal DATSCAN®. Caudate nucleus (C), putamen (P), and striatum (S) uptake values, C/P ratios, and asymmetry indexes (AI) were calculated using semi-quantitative methods. Outcomes were assessed according to age and gender, and reference limits were established using the percentile approach.

Results

A significant negative linear effect of age was found upon striatal nuclei uptake of 0.21–0.22 per decade (6.8 %/decade for striatum), whereas a potential gender influence proved unclear. Inferior reference limits were established at the 5th percentile. C/P ratios and AIs were not influenced by age or gender, and superior reference limits were set at the 95th percentile.

Conclusions

We here propose a convenient approach to calculate site-specific reference limits for DaTSCAN® outcomes not requiring scanning healthy controls. The method appears to yield robust values that range within nearly identical limits as those obtained in healthy subjects.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. 1.

    Booij J, Speelman JD, Horstink MW, Wolters EC (2001) The clinical benefit of imaging Striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 28:266–272

  2. 2.

    Booij J, Tissingh G, Boer GJ et al (1997) [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry 62:133–140

  3. 3.

    Benamer TS, Patterson J, Grosset DG et al (2000) Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]FP-CIT SPECT imaging: the [123I]FP-CIT study group. Mov Disord 15:503–510

  4. 4.

    Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R (2006) [123I]FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson’s disease. Mov Disord 21:510–514

  5. 5.

    Gerschlager W, Bencsits G, Pirker W et al (2002) [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson’s disease. Mov Disord 17:518–523

  6. 6.

    Vlaar AM, de Nijs T, Kessels AG et al (2008) Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with Parkinsonian syndromes. Eur Neurol 59:258–266

  7. 7.

    Brigo F, Matinella A, Erro R, Tinazzi M (2014) [123I]FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson’s disease and vascular or drug-induced parkinsonisms: a meta-analysis. Eur J Neurol 21:1369–e1390

  8. 8.

    Catafau AM, Tolosa E, Da TCUPSSG (2004) Impact of dopamine transporter SPECT using 123I-ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 19:1175–1182

  9. 9.

    Papathanasiou N, Rondogianni P, Chroni P et al (2012) Interobserver variability, and visual and quantitative parameters of 123I-FP-CIT SPECT (DaTSCAN) studies. Ann Nucl Med 26:234–240

  10. 10.

    Morton RJ, Guy MJ, Clauss R et al (2005) Comparison of different methods of DatSCAN quantification. Nucl Med Commun 26:1139–1146

  11. 11.

    Skanjeti A, Angusti T, Margheron M et al (2012) FP-CIT SPECT evaluation: time to go beyond visual assessment! Eur J Nucl Med Mol Imaging 39:727–728

  12. 12.

    Davidsson A, Georgiopoulos C, Dizdar N et al (2014) Comparison between visual assessment of dopaminergic degeneration pattern and semi-quantitative ratio calculations in patients with Parkinson’s disease and atypical Parkinsonian syndromes using DaTSCAN SPECT. Ann Nucl Med 28:851–859

  13. 13.

    Ottaviani S, Tinazzi M, Pasquin I et al (2006) Comparative analysis of visual and semi-quantitative assessment of striatal [123I]FP-CIT-SPET binding in Parkinson’s disease. Neurol Sci 27:397–401

  14. 14.

    Filippi L, Bruni C, Padovano F et al (2008) The value of semi-quantitative analysis of 123I-FP-CIT SPECT in evaluating patients with Parkinson’s disease. Neuroradiol J 21:505–509

  15. 15.

    Dickson JC, Tossici-Bolt L, Sera T et al (2012) Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database. Eur J Nucl Med Mol Imaging 39:188–197

  16. 16.

    Varrone A, Dickson JC, Tossici-Bolt L et al (2013) European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging 40:213–227

  17. 17.

    Nobili F, Naseri M, De Carli F et al (2013) Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. Eur J Nucl Med Mol Imaging 40:565–573

  18. 18.

    Hamilton D, List A, Butler T et al (2006) Discrimination between Parkinsonian syndrome and essential tremor using artificial neural network classification of quantified DaTSCAN data. Nucl Med Commun 27:939–944

  19. 19.

    Bajaj N, Hauser RA, Grachev ID (2013) Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of Parkinsonian syndromes. J Neurol Neurosurg Psychiatry 84:1288–1295

  20. 20.

    Brajkovic LD, Svetel MV, Kostic VS et al (2012) Dopamine transporter imaging (123)I-FP-CIT (DaTSCAN) SPET in differential diagnosis of dopa-responsive dystonia and young-onset Parkinson’s disease. Hell J Nucl Med 15:134–138

  21. 21.

    Deuschl G, Bain P, Brin M (1998) Consensus statement of the movement disorder society on tremor. Ad Hoc scientific committee. Mov Disord 13(Suppl 3):2–23

  22. 22.

    Morgante F, Edwards MJ, Espay AJ et al (2012) Diagnostic agreement in patients with psychogenic movement disorders. Mov Disord 27:548–552

  23. 23.

    Albanese A, Asmus F, Bhatia KP et al (2011) EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 18:5–18

  24. 24.

    Zijlmans JC, Daniel SE, Hughes AJ et al (2004) Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord 19:630–640

  25. 25.

    Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184

  26. 26.

    McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 65:1863–1872

  27. 27.

    Gilman S, Wenning GK, Low PA et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670–676

  28. 28.

    Litvan I, Agid Y, Calne D et al (1996) Clinical research criteria for the diagnosis of progressive Supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47:1–9

  29. 29.

    Boeve BF, Lang AE, Litvan I (2003) Corticobasal degeneration and its relationship to progressive Supranuclear palsy and frontotemporal dementia. Ann Neurol 54(Suppl 5):S15–S19

  30. 30.

    Zaidi H, Montandon ML (2002) Which attenuation coefficient to use in combined attenuation and scatter corrections for quantitative brain SPET? Eur J Nucl Med Mol Imaging 29:967–969, author reply 969–970

  31. 31.

    Radau PE, Slomka PJ, Julin P et al (2001) Evaluation of linear registration algorithms for brain SPECT and the errors due to hypoperfusion lesions. Med Phys 28:1660–1668

  32. 32.

    Koch W, Radau PE, Hamann C, Tatsch K (2005) Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. J Nucl Med 46:1109–1118

  33. 33.

    Garibotto V, Montandon ML, Viaud CT et al (2013) Regions of interest-based discriminant analysis of DaTSCAN SPECT and FDG-PET for the classification of dementia. Clin Nucl Med 38:e112–e117

  34. 34.

    Eusebio A, Azulay J-P, Ceccaldi M et al (2012) Voxel-based analysis of whole-brain effects of age and gender on dopamine transporter SPECT imaging in healthy subjects. Eur J Nucl Med Mol Imaging 39:1778–1783

  35. 35.

    Tissingh G, Bergmans P, Booij J et al (1997) [123I]beta-CIT single-photon emission tomography in Parkinson’s disease reveals a smaller decline in dopamine transporters with age than in controls. Eur J Nucl Med 24:1171–1174

  36. 36.

    van Dyck CH, Seibyl JP, Malison RT et al (1995) Age-related decline in Striatal dopamine transporter binding with iodine-123-beta-CITSPECT. J Nucl Med 36:1175–1181

  37. 37.

    van Dyck CH, Seibyl JP, Malison RT et al (2002) Age-related decline in dopamine transporters: analysis of Striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 10:36–43

  38. 38.

    Gunning-Dixon FM, Head D, McQuain J et al (1998) Differential aging of the human striatum: a prospective MR imaging study. AJNR Am J Neuroradiol 19:1501–1507

  39. 39.

    Vermeulen RJ, Wolters EC, Tissingh G et al (1995) Evaluation of [123I] beta-CIT binding with SPECT in controls, early and late Parkinson’s disease. Nucl Med Biol 22:985–991

  40. 40.

    Volkow ND, Ding YS, Fowler JS et al (1996) Dopamine transporters decrease with age. J Nucl Med 37:554–559

  41. 41.

    Lavalaye J, Booij J, Reneman L et al (2000) Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med 27:867–869

  42. 42.

    Staley JK, Krishnan-Sarin S, Zoghbi S et al (2001) Sex differences in [123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse 41:275–284

  43. 43.

    Mozley LH, Gur RC, Mozley PD, Gur RE (2001) Striatal dopamine transporters and cognitive functioning in healthy men and women. Am J Psychiatry 158:1492–1499

  44. 44.

    Ryding E, Lindstrom M, Bradvik B et al (2004) A new model for separation between brain dopamine and serotonin transporters in 123I-beta-CIT SPECT measurements: normal values and sex and age dependence. Eur J Nucl Med Mol Imaging 31:1114–1118

  45. 45.

    El Fakhri G, Habert MO, Maksud P et al (2006) Quantitative simultaneous 99mTc-ECD/123I-FP-CIT SPECT in Parkinson’s disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 33:87–92

  46. 46.

    Sixel-Doring F, Liepe K, Mollenhauer B et al (2011) The role of 123I-FP-CIT-SPECT in the differential diagnosis of parkinson and tremor syndromes: a critical assessment of 125 cases. J Neurol 258:2147–2154

  47. 47.

    Contrafatto D, Mostile G, Nicoletti A et al (2012) [(123) I]FP-CIT-SPECT asymmetry index to differentiate Parkinson’s disease from vascular parkinsonism. Acta Neurol Scand 126:12–16

  48. 48.

    Benitez-Rivero S, Marin-Oyaga VA, Garcia-Solis D et al (2013) Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson’s disease. J Neurol Neurosurg Psychiatry 84:122–129

  49. 49.

    Shin HY, Kang SY, Yang JH et al (2007) Use of the putamen/caudate volume ratio for early differentiation between Parkinsonian variant of multiple system atrophy and parkinson disease. J Clin Neurol 3:79–81

  50. 50.

    Haapaniemi TH, Ahonen A, Torniainen P et al (2001) [123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated Parkinsonian patients. Mov Disord 16:124–130

  51. 51.

    Jakobson Mo S, Larsson A, Linder J et al (2013) (1)(2)(3)I-FP-Cit and 123I-IBZM SPECT uptake in a prospective normal material analysed with two different semiquantitative image evaluation tools. Nucl Med Commun 34:978–989

Download references

Acknowledgments

None.

Conflict of Interest

The authors state that they have no conflict of interest.

Author information

Correspondence to Pierre R. Burkhard.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nicastro, N., Garibotto, V., Poncet, A. et al. Establishing On-Site Reference Values for 123I-FP-CIT SPECT (DaTSCAN®) Using a Cohort of Individuals with Non-Degenerative Conditions. Mol Imaging Biol 18, 302–312 (2016). https://doi.org/10.1007/s11307-015-0889-6

Download citation

Key words

  • SPECT
  • Reference values
  • Dopaminergic uptake
  • Gender
  • Age